Opexa Therapeutics Inc. (Nasdaq: OPXA) reported disappointing results from a Phase 2b Abili-T clinical trial of Tcelna in patients with secondary progressive multiple sclerosis. Shares of the biopharmaceutical tumbled $2.35 to close at $1.05.
Opexa's Tcelna fails Phase 2b trial
October 28, 2016 at 17:34 PM EDT
